Metabolic reprogramming in cancer cells, consequences on pH and tumour progression: Integrated therapeutic perspectives with dietary lipids as adjuvant to anticancer treatment.
While tumours arise from acquired mutations in oncogenes or tumour-suppressor genes, it is clearly established that cancers are metabolic diseases characterized by metabolic alterations in tumour cells, and also non-tumour cells of the host organism resulting in tumour cachexia and patient weakness. In this review, we aimed at delineating details by which metabolic alterations in cancer cells, characterized by mitochondrial bioenergetics deregulations and the preference for aerobic glycolysis, are critical parameters controlling the aggressive progression of tumours. In particular, metabolic alteration in cancer cells are coupled to the modulation of intracellular and extracellular pH, epithelial-to-mesenchymal transition and associated increased invasiveness, autophagy, and the development of anticancer treatment resistance. Finally, based on mechanistic, pre-clinical and clinical studies, we proposed the adjuvant supplementation of dietary n-3 polyunsaturated fatty acids for a complementary holistic treatment of the cancer disease.
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; UFR Sciences Pharmaceutiques, Université François-Rabelais de Tours, Avenue Monge, 37200 Tours, France.
Jean-François
JF
Dumas
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France.
Lucie
L
Brisson
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; UFR Sciences Pharmaceutiques, Université François-Rabelais de Tours, Avenue Monge, 37200 Tours, France.
Stéphan
S
Chevalier
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; UFR Sciences Pharmaceutiques, Université François-Rabelais de Tours, Avenue Monge, 37200 Tours, France.
Karine
K
Mahéo
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; Service d'anatomie et cytologie pathologiques, CHU de Tours, 37044 Tours cedex 9, France.
Gaëlle
G
Fromont
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; Service d'hépato-gastroentérologie et de cancérologie digestive, CHU de Tours, 37044 Tours cedex 9, France.
Driffa
D
Moussata
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; UFR Sciences Pharmaceutiques, Université François-Rabelais de Tours, Avenue Monge, 37200 Tours, France.
Pierre
P
Besson
Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; Département de Physiologie Animale, UFR Sciences et Techniques, Université François-Rabelais de Tours, Avenue Monge, 37200 Tours, France; Institut Universitaire de France, 1 rue Descartes, 75231 Paris, France. Electronic address: sebastien.roger@univ-tours.fr.
Sébastien
S
Roger
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004041:Dietary Fats / Q000008:administration & dosage*; D018450:Disease Progression; D058750:Epithelial-Mesenchymal Transition; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008928:Mitochondria / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D000970:Antineoplastic Agents; D004041:Dietary Fats
Cancer cell invasiveness; Cancer cell metabolism; N-3 polyunsaturated fatty acids; Resistance to treatments; pH